Wenrui Deng1, Die Hu1, Sheng Xu1, Xiaoyu Liu1, Jingwen Zhao1, Qian Chen1, Jiayuan Liu2, Zheng Zhang2, Wenxiu Jiang3, Lijun Ma4, Xinyi Hong5, Shengrong Cheng5, Boya Liu5, Xiaoming Li6. 1. Department of Medical Psychology, Chaohu Clinical Medical College, Anhui Medical University, Hefei, Anhui 230032, China. 2. Department of Medical Anesthesia, the First Clinical Medical College of Anhui Medical University, Hefei, Anhui 230032, China. 3. Department of Stomatology, Stomatology College of Anhui Medical University, Hefei, Anhui 230032, China. 4. Department of Psychology, School of Education, Anqing Normal University, Anqing, Anhui 246133, China. 5. Department of Clinical Medical, the First Clinical Medical College, Anhui Medical University, Hefei, Anhui 230032, China. 6. Department of Medical Psychology, Chaohu Clinical Medical College, Anhui Medical University, Hefei, Anhui 230032, China. Electronic address: psyxiaoming@126.com.
Abstract
BACKGROUND: Virtual reality exposure therapy (VRET) for PTSD is an emerging treatment of remarkable promise, but its efficacy and safety are still unclear. Our aim was to investigate the efficacy of VRET for individuals with PTSD, and to identify the potential moderating variables associated with interventions. METHODS: Literature search was conducted via PubMed, Embase, Web of Science, Cochrane Library, PsycInfo, Science Direct, and EBSCO. We identified 18 studies on PTSD including 13 randomized controlled trials (RCTs; 654 participants) and 5 single-group trials (60 participants). RESULTS: The main effects analysis showed a moderate effect size (g = 0.327, 95% CI: 0.105-0.550, p<0.01) for VRET compared to control conditions on PTSD symptoms. Subgroup analysis revealed that the effects of VRET were larger when compared to inactive groups (g = 0.567) than active control groups (g = 0.017). This finding was in agreement with depressive symptoms. A dose-response relationship existed with more VRET sessions showing larger effects. There was a long-range effect of VRET on PTSD symptoms indicating a sustained decrease in PTSD symptoms at 3-month follow-up (g = 0.697) and 6-month follow-up (g = 0.848). The single-group trials analysis revealed that the VRET intervention had a significant effect on PTSD. LIMITATIONS: Many of the combat-related PTSD subjects resulted in uncertainty regarding meta-analytical estimates and subsequent conclusions. CONCLUSIONS: These findings demonstrated that VRET could produce significant PTSD symptoms reduction and supported its application in treating PTSD.
BACKGROUND: Virtual reality exposure therapy (VRET) for PTSD is an emerging treatment of remarkable promise, but its efficacy and safety are still unclear. Our aim was to investigate the efficacy of VRET for individuals with PTSD, and to identify the potential moderating variables associated with interventions. METHODS: Literature search was conducted via PubMed, Embase, Web of Science, Cochrane Library, PsycInfo, Science Direct, and EBSCO. We identified 18 studies on PTSD including 13 randomized controlled trials (RCTs; 654 participants) and 5 single-group trials (60 participants). RESULTS: The main effects analysis showed a moderate effect size (g = 0.327, 95% CI: 0.105-0.550, p<0.01) for VRET compared to control conditions on PTSD symptoms. Subgroup analysis revealed that the effects of VRET were larger when compared to inactive groups (g = 0.567) than active control groups (g = 0.017). This finding was in agreement with depressive symptoms. A dose-response relationship existed with more VRET sessions showing larger effects. There was a long-range effect of VRET on PTSD symptoms indicating a sustained decrease in PTSD symptoms at 3-month follow-up (g = 0.697) and 6-month follow-up (g = 0.848). The single-group trials analysis revealed that the VRET intervention had a significant effect on PTSD. LIMITATIONS: Many of the combat-related PTSD subjects resulted in uncertainty regarding meta-analytical estimates and subsequent conclusions. CONCLUSIONS: These findings demonstrated that VRET could produce significant PTSD symptoms reduction and supported its application in treating PTSD.
Authors: Gigi Toh; Eiluned Pearce; John Vines; Sarah Ikhtabi; Mary Birken; Alexandra Pitman; Sonia Johnson Journal: BMC Psychiatry Date: 2022-05-12 Impact factor: 4.144
Authors: Theresa Brown; Emily Nauman Vogel; Debra L Safer; Cristin D Runfola; Sarah Adler; Cara Bohon; Kim Bullock; Katherine Nameth; Giuseppe Riva Journal: J Med Internet Res Date: 2020-04-23 Impact factor: 5.428
Authors: Johan H Vlake; Evert-Jan Wils; Jasper van Bommel; Tim I M Korevaar; Diederik Gommers; Michel E van Genderen Journal: Crit Care Explor Date: 2021-05-12